You are viewing a preview of this job. Log in or register to view more details about this job.

FDA Antibacterial Drug Resistance Micro-Epidemiology Fellowship

*Applications will be reviewed on a rolling-basis.

A research opportunity is available in the Office of New Drugs/Office of Antimicrobial Products, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

Antibacterial drug resistance is a major threat to public health. In March 2015, The National Action Plan for Combating Antibiotic-resistant Bacteria was developed in response to Executive Order 13676: Combating Antibiotic-Resistant Bacteria (CARB), which was issued on September 18, 2014. The National Action Plan outlines steps for implementing the National Strategy for Combating Antibiotic-Resistant Bacteria to address urgent and serious drug-resistant threats that affect people in the U.S. and around the world. Implementation of the National Action Plan will also support World Health Assembly resolution 67.25 (Antimicrobial Resistance), which urges countries to take urgent action at the national, regional, and local levels to combat resistance.

FDA’s roles in combatting antibacterial drug resistance are to: (1) facilitate the development of new antibacterial drugs to treat patients and (2) advance the science of clinical trial design.

As part of ongoing efforts to harmonize and facilitate the global development of antibacterial drugs, a research project will examine the microbial etiologies of bacterial infections such as hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, community-acquired bacterial pneumonia, complicated urinary tract infections, and complicated intra-abdominal infections in different geographic regions. The epidemiology of resistance phenotypes in different geographic regions will also be evaluated as part of this project.

Under the guidance of a mentor, the selected participant will perform research analysis in conducting comparative epidemiologic analysis of bacterial causes of serious bacterial infections and resistance phenotypes in different geographical regions.

Qualifications
The qualified candidate should have received a master's or doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date. 

Preferred skills:
  • Ability to think critically
  • Strong analytical skills to evaluate complex information relating to the safety and efficacy of drugs, e.g. understanding the mechanism of action of drugs and antimicrobial activity and clinical outcomes
  • Excellent written and oral communication skills to effectively communicate complex research findings and recommendations
  • Knowledge in clinical microbiology and epidemiology

If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity (FDA-CDER-2020-0505) in your email.